Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHF6001 (Tanimilast) in COPD with chronic bronchitis
NCT04636814Phase 3Terminated
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Jul 2021
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 28
01
Overview
Phase 3, randomised, double-blind trial of tanimilast in chronic obstructive pulmonary disease (COPD) (4 arms), sponsored by Chiesi Farmaceutici S.p.A. Primary endpoint: Number of moderate and severe exacerbations at 52 weeks. Started Jul 2021; status: terminated.
02
Drugs
tanimilast
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT04636814.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04636814.